SCHEMBL185738

SCHEMBL185738

CP(=O)(O)C[C@@H](O)CN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL185737 1.00
SCHEMBL185739 1.00
Methyl Phosphonate SCHEMBL11583582 0.81 GABBR2 (0.68)
SCHEMBL31406285 0.79
SCHEMBL3420169 0.79
SCHEMBL1884027 0.75
SCHEMBL1883346 0.75
SCHEMBL1890961 0.75
Hydrochloric Acid SCHEMBL6349414 0.75 GABBR2 (0.59)
SCHEMBL14803453 0.73 GABBR2 (0.58)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250186401-A1 COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2025-06-12 US claimed
US-20240390311-A1 COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-11-28 US claimed
EP-4405049-A1 COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS The Regents of the University of California (US) 2024-07-31 EP claimed
US-20230381125-A1 COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-11-30 US claimed
WO-2023178183-A1 COMBINATORIAL ACTIVATION OF GABA(B) AND ALPHA-2 ADRENERGIC RECEPTORS FOR TREATMENT OF STRESS INDUCED DEPRESSION UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2023-09-21 WO claimed
EP-4217002-A1 COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS The Regents of the University of California (US) 2023-08-02 EP claimed
WO-2023101899-A1 COMPOSITIONS AND METHODS FOR AMELIORATING SJOGREN'S SYNDROME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-08 WO claimed
WO-2023048781-A1 COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-03-30 WO claimed
WO-2022067044-A1 COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-03-31 WO claimed
US-20210205248-A1 GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-07-08 US claimed
WO-2012050907-A2 GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-04-19 WO claimed
US-7494985-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use XENOPORT, INC. (US) 2009-02-24 US claimed
US-20060111325-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use XENOPORT, INC. 2006-05-25 US claimed
WO-2006050472-A2 ACYLOXYALKYL CARBAMATE PRODRUGS OF 3-AMINOPROPYLPHOSPHONOUS AND -PHOSPHINIC ACIDS XENOPORT, INC. (US) 2006-05-11 WO claimed
JP-2003516346-A 2003-05-13 JP claimed
EP-1239843-A1 NEW (AMINOPROPYL)METHYLPHOSPHINIC ACIDS AstraZeneca AB (SE) 2002-09-18 EP claimed
WO-2001041743-A1 NEW (AMINOPROPYL)METHYLPHOSPHINIC ACIDS ASTRAZENECA AB (SE) 2001-06-14 WO claimed
US-5567840-A AS 4-AMINOBUTYRIC ACID AGONIST; MUSCLE RELAXANTS CIBA-GEIGY CORPORATION (US) 1996-10-22 US claimed
EP-0399949-B1 Substituted aminoalkylphosphinic acids CIBA GEIGY AG (CH) 1995-04-12 EP claimed
EP-0399949-A1 Substituted aminoalkylphosphinic acids CIBA-GEIGY AG (CH) 1990-11-28 EP claimed